Alnylam Pharmaceuticals, Inc. (ALNY) financials

Alnylam Pharmaceuticals, Inc. (ALNY) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2025, Alnylam Pharmaceuticals, Inc. reported revenue of $3.71B, up 65.2% year over year, net income of $314M, diluted EPS of $2.33 and free cash flow of $465M.

Revenue (fiscal 2025)

$3.71B

Revenue growth (fiscal 2025)

65.2%

Net income (fiscal 2025)

$314M

Diluted EPS (fiscal 2025)

$2.33

Free cash flow (fiscal 2025)

$465M

Alnylam Pharmaceuticals, Inc. files with the U.S. Securities and Exchange Commission under CIK 0001178670, classified as Pharmaceutical Preparations.

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.